1-4 of 4
Xenia Naj
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

In vitro evidence supporting the use of exogenous IL-2 support for allogeneic UCART22 cells to treat heavily pretreated R/R B-ALL patients

Free
Laurent Poirot, Pauline Vermeulen, Xenia Naj, Shipra Das, Adrian Kilcoyne
Journal: Blood
Blood (2025) 146 (Supplement 1): 7640.
https://doi.org/10.1182/blood-2025-7640
Published: 2025
Journal Articles

Weight based dosing of alemtuzumab as part of an enhanced lymphodepletion regimen may  mitigate the risks of over and underexposure and improve response rates : Analysis of the nathali-01 trial

Free
Xenia Naj, Laurent Poirot, Vivian Dai, Pauline Vermeulen, Sophie Ramadier, Adrian Kilcoyne
Journal: Blood
Blood (2025) 146 (Supplement 1): 7240.
https://doi.org/10.1182/blood-2025-7240
Published: 2025
Journal Articles

Increased alemtuzumab exposure correlates with improved responses in heavily pretreated R/R ALL patients: Analysis of the balli-01 trial

Free
Nitin Jain, Nicolas Boissel, Daniel Deangelo, Aravind Ramakrishnan, Laurent Poirot, Xenia Naj, Carolyn Figliola, Adrian Kilcoyne
Journal: Blood
Blood (2025) 146 (Supplement 1): 5952.
https://doi.org/10.1182/blood-2025-5952
Published: 2025
Journal Articles

Trial in progress: Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) nathali-01

Free
Jeremy Abramson, Aravind Ramakrishnan, Emmanuel Bachy, Laurent Poirot, Xenia Naj, Vivian Dai, Sophie Ramadier, Adrian Kilcoyne
Journal: Blood
Blood (2025) 146 (Supplement 1): 3731.
https://doi.org/10.1182/blood-2025-3731
Published: 2025